Last updated: February 22, 2026
Overview of the Product
NDC 70700-0164 is a prescription drug marketed primarily for [specific indication, e.g., autoimmune disease, cancer, or other therapeutic area]. The drug is produced by [manufacturer], approved by the FDA in [approval year], and is classified under [drug class or category].
Market Landscape
Therapeutic Area and Competition
The drug targets a $[market size in USD] global market with an annual growth rate of [% relevant CAGR, e.g., 8%]. Key competitors include [list major competitors], with market shares of approximately [percentage shares].
Patient Population
Estimated at [number], the patient base comprises [demographics, such as age groups, disease prevalence]. The prevalence rate of the corresponding condition is [percentage], with treatment penetration at [percentage].
Regulatory Environment
The drug has [status, e.g., orphan drug designation, patent protection until specific year], influencing market exclusivity. Recent policy developments, such as [new FDA guidelines, pricing regulations], could impact market dynamics.
Pricing Landscape
Current Pricing
As of Q1 2023, the wholesale acquisition cost (WAC) for NDC 70700-0164 stands at approximately $[current price] per unit. The average retail price is estimated at $[retail price], with payer discounts reducing net prices to roughly $[net price].
Price Trends
Over the past 24 months, prices have increased by [%], driven by factors such as manufacturing costs, market demand, and regulatory approval for expanded indications.
Benchmark Comparisons
Comparative prices for similar drugs:
- Drug A: $[price] per dose
- Drug B: $[price] per dose
- Drug C: $[price] per dose
This positions NDC 70700-0164 within a competitive range of [$[min-price]]–[$[max-price]].
Market Projections
Short-Term (Next 1–2 Years)
Market penetration is expected to grow from [current percentage] to approximately [%], driven by [expanding indications, increased prescribing, pricing adjustments]. Revenue projections forecast an increase from $[current revenue] to about $[projected revenue].
Long-Term (3–5 Years)
By 2026, sales are projected to reach $[long-term revenue], assuming:
- Increased adoption owing to expanded indications
- Competitive pricing adjustments
- Regulatory changes facilitating broader access
Volume and Revenue Forecasts
| Year |
Units Sold (millions) |
Revenue (USD millions) |
Market Share (%) |
| 2023 |
[number] |
[$amount] |
[%] |
| 2024 |
[number] |
[$amount] |
[%] |
| 2025 |
[number] |
[$amount] |
[%] |
| 2026 |
[number] |
[$amount] |
[%] |
Risks and Opportunities
Factors positively influencing growth include FDA approval of new indications and favorable reimbursement policies; risks involve patent expiry, generic entry, and pricing pressures.
Key Takeaways
- NDC 70700-0164 has a current WAC around $[price], with a retail price near $[price].
- The drug's market size is approximately $[market size], with growth driven by expanding indications.
- Market share is expected to increase as adoption broadens, with sales potentially reaching $[long-term revenue] by 2026.
- Price competition and regulatory developments remain pivotal in shaping future profitability.
FAQs
-
What therapeutic area does NDC 70700-0164 target?
It targets [specific indication], competing with similar products in the [therapeutic class].
-
How does the price compare to its competitors?
It falls within the $[price range], aligning with or slightly exceeding similar drugs in its class.
-
What factors could influence its market growth?
Expanded indications, regulatory approvals, and reimbursement policies.
-
What are the major risks to its market expansion?
Patent expiration, biosimilar/generic entry, and pricing pressures.
-
What is the projected revenue by 2026?
Approximately $[projected revenue], assuming current growth trends continue.
References
[1] U.S. Food and Drug Administration. (2022). [Approval and regulatory details].
[2] IQVIA. (2022). Market analysis and sales data for therapeutic area.
[3] SSR Health. (2023). Average wholesale prices and net pricing reports.
[4] Evaluate Pharma. (2023). Market forecasts and sales projections.
[5] Centers for Disease Control and Prevention. (2022). Disease prevalence and patient demographics.
